Article Text

Download PDFPDF
Adding buprenorphine implants to counselling reduces opioid use over 6 months in opioid-dependent adults

Statistics from


  • Source of funding Titan Pharmaceuticals.


  • Competing interests DF has received honoraria for serving on an external advisory board designed to monitor diversion and abuse of buprenorphine.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.